mitomycin has been researched along with Nasopharyngeal Neoplasms in 20 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice." | 7.78 | A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. ( Cao, Q; Chen, RJ; Feng, ZQ; Mao, Y; Wen, J; Zhang, DW; Zhu, J, 2012) |
| "Between August 1990 and December 1997, 25 patients with stage III and IV nasopharyngeal carcinoma received an accelerated and hyperfractionated radiotherapy with concurrent chemotherapy (5-FU and mitomycin C)." | 5.09 | Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study. ( Budach, V; Fischer, M; Jahnke, K; Klahold, M; Sack, H; Stüben, G; Stuschke, M, 2001) |
| " The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice." | 3.78 | A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. ( Cao, Q; Chen, RJ; Feng, ZQ; Mao, Y; Wen, J; Zhang, DW; Zhu, J, 2012) |
| "Liver metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR) (P = 0." | 2.69 | Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. ( Hong, RL; Hsu, MM; Ko, JY; Sheen, TS; Ting, LL; Wang, CC, 1999) |
| "Choanal stenosis is a well recognized late complication of radiotherapy for nasopharyngeal carcinoma." | 1.39 | Velopharyngeal and choanal stenosis after radiotherapy for nasopharyngeal carcinoma. ( Chong, AW; Hussein, J; Narayanan, P; Omar, R; Tan, TS, 2013) |
| "To gain direct evidence that genomic instability is involved in the induction of SLCCs, we utilized multiple approaches to enhance genomic instability and monitored the percentage of SLCC in cultured cancer cells." | 1.36 | Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. ( Cao, J; Deng, W; Huang, Y; Kang, T; Liang, Y; Liu, Q; Pei, D; Tsao, G; Zeng, YX; Zhong, Z, 2010) |
| "Mitomycin-C application has being shown useful adjunct to surgical technique in managing nasopharyngeal stenosis for surgeons." | 1.35 | Velopharyngeal stenosis, a late complication of radiotherapy. ( Kumar, SS; Lee, SC; Singh, A; Singh, S; Tang, IP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patterson, JM | 1 |
| McColl, E | 1 |
| Carding, PN | 1 |
| Hildreth, AJ | 1 |
| Kelly, C | 1 |
| Wilson, JA | 1 |
| Twu, CW | 1 |
| Wang, WY | 1 |
| Chen, CC | 1 |
| Liang, KL | 1 |
| Jiang, RS | 1 |
| Wu, CT | 1 |
| Shih, YT | 1 |
| Lin, PJ | 1 |
| Liu, YC | 1 |
| Lin, JC | 1 |
| Huang, J | 1 |
| Li, Q | 1 |
| Zheng, Y | 1 |
| Shen, J | 1 |
| Li, B | 1 |
| Zou, R | 1 |
| Wang, J | 1 |
| Yuan, Y | 1 |
| Lee, SC | 1 |
| Tang, IP | 1 |
| Singh, A | 1 |
| Kumar, SS | 1 |
| Singh, S | 1 |
| Liang, Y | 1 |
| Zhong, Z | 1 |
| Huang, Y | 1 |
| Deng, W | 1 |
| Cao, J | 1 |
| Tsao, G | 1 |
| Liu, Q | 1 |
| Pei, D | 1 |
| Kang, T | 1 |
| Zeng, YX | 1 |
| Chen, R | 1 |
| Zhang, D | 1 |
| Mao, Y | 2 |
| Zhu, J | 2 |
| Ming, H | 1 |
| Wen, J | 2 |
| Ma, J | 1 |
| Cao, Q | 2 |
| Lin, H | 1 |
| Tang, Q | 1 |
| Liang, J | 1 |
| Feng, Z | 1 |
| Zhang, DW | 1 |
| Chen, RJ | 1 |
| Feng, ZQ | 1 |
| Hussein, J | 1 |
| Tan, TS | 1 |
| Chong, AW | 1 |
| Narayanan, P | 1 |
| Omar, R | 1 |
| Hsu, CH | 1 |
| Chen, CL | 1 |
| Hong, RL | 3 |
| Chen, KL | 1 |
| Lin, JF | 1 |
| Cheng, AL | 1 |
| KOOP, CE | 1 |
| TEWARSON, IP | 1 |
| Zhang, X | 1 |
| Ling, MT | 1 |
| Wong, YC | 1 |
| Wang, X | 1 |
| Shimada, F | 1 |
| Turner, SL | 1 |
| Tiver, KW | 1 |
| Sheen, TS | 2 |
| Ko, JY | 2 |
| Hsu, MM | 2 |
| Wang, CC | 2 |
| Ting, LL | 2 |
| Fischer, M | 1 |
| Stüben, G | 1 |
| Klahold, M | 1 |
| Stuschke, M | 1 |
| Budach, V | 1 |
| Sack, H | 1 |
| Jahnke, K | 1 |
| Lou, PJ | 1 |
| Chung, NN | 1 |
| Lui, LT | 1 |
| Narasimha, K | 1 |
| Schifter, M | 1 |
| Barrett, AP | 1 |
| Souhami, L | 1 |
| Rabinowits, M | 1 |
| Tsukuda, M | 1 |
| Sawaki, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolization, Th | 2014 |
3 trials available for mitomycin and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin | 1999 |
Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Dose | 2001 |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2001 |
16 other studies available for mitomycin and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Swallowing in the first year after chemoradiotherapy for head and neck cancer: clinician- and patient-reported outcomes.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Deglutition; Deglutition Disorders | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Velopharyngeal stenosis, a late complication of radiotherapy.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Choanal Atresia; Combi | 2009 |
Stem-like cancer cells are inducible by increasing genomic instability in cancer cells.
Topics: AC133 Antigen; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Ca | 2010 |
A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma; Cell Line, Tumor; Cell Prolifer | 2012 |
A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor.
Topics: Animals; Antibodies; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Dr | 2012 |
Velopharyngeal and choanal stenosis after radiotherapy for nasopharyngeal carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cicatrix; Constriction, Pathologic; Endoscopy; Female; Human | 2013 |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2002 |
RHABDOMYOSARCOMA OF THE HEAD AND NECK IN CHILDREN.
Topics: Adolescent; Child; Cyclophosphamide; Dactinomycin; Facial Neoplasms; Facial Paralysis; Head; Head an | 1964 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, | 2007 |
[Nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1984 |
Synchronous radiotherapy and chemotherapy in the treatment of nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1993 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Multiple cranial nerve involvement leading to diagnosis of nasopharyngeal carcinoma: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cranial Nerves; Deglutition Disorders; Fl | 1992 |
Combined treatment in carcinoma of the nasopharynx.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
Immunological basis and immunotherapy of nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Monoclonal; Biological Products; Cell Line; Humans; Immunity, Cellular; Interleuk | 1985 |